K
Overview
Kriya Therapeutics develops gene therapies for widespread diseases and monetizes these programs through licensing and collaboration agreements. Its gene therapies target genetic or biological drivers of conditions such as Geographic Atrophy, Diabetic Retinopathy, and NASH, with a focus on ophthalmology. The company advances programs by partnering with biotech and pharma companies to secure upfront payments, milestones, and potential royalties. Its goal is to become a leading gene therapy biopharmaceutical company by delivering safe, effective treatments and generating revenue through collaborations and eventual product sales.
Work here?Claim your company
Simplify's take
What believers are saying
- Kriya raised $320 million in September 2025, extending runway and manufacturing buildout.
- The June 2026 FDA PreCheck selection validates its commercial facility strategy and regulatory readiness.
- 2026 recruiting trials for GA, TED, and trigeminal neuralgia expand near-term clinical catalysts.
What critics are saying
- Kriya remains precommercial; every lead asset still depends on unproven clinical readouts through 2029.
- The three-year TED, TN, and GA trials create long financing risk after the 2025 Series D.
- A negative safety signal in ocular or CNS AAV delivery would cripple the entire platform.
What makes Kriya Therapeutics unique
- Kriya runs five clinical programs across ophthalmology, neurology, and metabolic disease in 2026.
- Its fully integrated AAV manufacturing platform won FDA PreCheck selection on June 29, 2026.
- KRIYA-825 uses suprachoroidal delivery, aiming for outpatient dosing in geographic atrophy.
Help us improve and share your feedback! Did you find this helpful?